Surmodics Inc
NASDAQ:SRDX

Watchlist Manager
Surmodics Inc Logo
Surmodics Inc
NASDAQ:SRDX
Watchlist
Price: 39.33 USD 0.36% Market Closed
Market Cap: 561.1m USD
Have any thoughts about
Surmodics Inc?
Write Note

Intrinsic Value

The intrinsic value of one SRDX stock under the Base Case scenario is 15.29 USD. Compared to the current market price of 39.33 USD, Surmodics Inc is Overvalued by 61%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SRDX Intrinsic Value
15.29 USD
Overvaluation 61%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Surmodics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SRDX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SRDX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Surmodics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Surmodics Inc

Provide an overview of the primary business activities
of Surmodics Inc.

What unique competitive advantages
does Surmodics Inc hold over its rivals?

What risks and challenges
does Surmodics Inc face in the near future?

Has there been any significant insider trading activity
in Surmodics Inc recently?

Summarize the latest earnings call
of Surmodics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Surmodics Inc.

Provide P/S
for Surmodics Inc.

Provide P/E
for Surmodics Inc.

Provide P/OCF
for Surmodics Inc.

Provide P/FCFE
for Surmodics Inc.

Provide P/B
for Surmodics Inc.

Provide EV/S
for Surmodics Inc.

Provide EV/GP
for Surmodics Inc.

Provide EV/EBITDA
for Surmodics Inc.

Provide EV/EBIT
for Surmodics Inc.

Provide EV/OCF
for Surmodics Inc.

Provide EV/FCFF
for Surmodics Inc.

Provide EV/IC
for Surmodics Inc.

Show me price targets
for Surmodics Inc made by professional analysts.

What are the Revenue projections
for Surmodics Inc?

How accurate were the past Revenue estimates
for Surmodics Inc?

What are the Net Income projections
for Surmodics Inc?

How accurate were the past Net Income estimates
for Surmodics Inc?

What are the EPS projections
for Surmodics Inc?

How accurate were the past EPS estimates
for Surmodics Inc?

What are the EBIT projections
for Surmodics Inc?

How accurate were the past EBIT estimates
for Surmodics Inc?

Compare the revenue forecasts
for Surmodics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Surmodics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Surmodics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Surmodics Inc compared to its peers.

Compare the P/E ratios
of Surmodics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Surmodics Inc with its peers.

Analyze the financial leverage
of Surmodics Inc compared to its main competitors.

Show all profitability ratios
for Surmodics Inc.

Provide ROE
for Surmodics Inc.

Provide ROA
for Surmodics Inc.

Provide ROIC
for Surmodics Inc.

Provide ROCE
for Surmodics Inc.

Provide Gross Margin
for Surmodics Inc.

Provide Operating Margin
for Surmodics Inc.

Provide Net Margin
for Surmodics Inc.

Provide FCF Margin
for Surmodics Inc.

Show all solvency ratios
for Surmodics Inc.

Provide D/E Ratio
for Surmodics Inc.

Provide D/A Ratio
for Surmodics Inc.

Provide Interest Coverage Ratio
for Surmodics Inc.

Provide Altman Z-Score Ratio
for Surmodics Inc.

Provide Quick Ratio
for Surmodics Inc.

Provide Current Ratio
for Surmodics Inc.

Provide Cash Ratio
for Surmodics Inc.

What is the historical Revenue growth
over the last 5 years for Surmodics Inc?

What is the historical Net Income growth
over the last 5 years for Surmodics Inc?

What is the current Free Cash Flow
of Surmodics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Surmodics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Surmodics Inc

Current Assets 81.3m
Cash & Short-Term Investments 40.1m
Receivables 23.2m
Other Current Assets 18m
Non-Current Assets 97.3m
PP&E 25m
Intangibles 68.2m
Other Non-Current Assets 4.1m
Current Liabilities 20.5m
Other Current Liabilities 20.5m
Non-Current Liabilities 39.1m
Long-Term Debt 29.6m
Other Non-Current Liabilities 9.6m
Efficiency

Earnings Waterfall
Surmodics Inc

Revenue
126.1m USD
Cost of Revenue
-33m USD
Gross Profit
93.1m USD
Operating Expenses
-98.7m USD
Operating Income
-5.6m USD
Other Expenses
-5.9m USD
Net Income
-11.5m USD

Free Cash Flow Analysis
Surmodics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Surmodics reported robust revenue growth of 18% year-over-year at $32 million, mainly driven by a 40% increase in medical device product sales. Key products like SurVeil DCB and Pounce thrombectomy significantly contributed. The company improved its fiscal 2024 guidance to $122–$124 million, expecting operational revenue growth of 15% to 17%. GAAP net income turned positive to $250,000 from a $7.7 million loss last year. They also ended the quarter with $40.9 million in cash. Surmodics aims for sustained growth and continued investments in their vascular interventions portfolio.

What is Earnings Call?
Fundamental Scores

SRDX Profitability Score
Profitability Due Diligence

Surmodics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROIC
34/100
Profitability
Score

Surmodics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

SRDX Solvency Score
Solvency Due Diligence

Surmodics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
78/100
Solvency
Score

Surmodics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SRDX Price Targets Summary
Surmodics Inc

Wall Street analysts forecast SRDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SRDX is 43.86 USD with a low forecast of 43.43 USD and a high forecast of 45.15 USD.

Lowest
Price Target
43.43 USD
10% Upside
Average
Price Target
43.86 USD
12% Upside
Highest
Price Target
45.15 USD
15% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SRDX?

Click here to dive deeper.

Dividends

Surmodics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SRDX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SRDX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Surmodics Inc Logo
Surmodics Inc

Country

United States of America

Industry

Health Care

Market Cap

561.1m USD

Dividend Yield

0%

Description

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

Contact

MINNESOTA
Eden Prairie
9924 W 74th St
+19525007000.0
www.surmodics.com

IPO

1998-03-04

Employees

389

Officers

CEO, President & Director
Mr. Gary R. Maharaj
Senior VP of Finance & Information Technology and CFO
Mr. Timothy J. Arens
Senior VP of Legal, General Counsel & Secretary
Mr. Gordon S. Weber J.D.
Senior VP & President of Medical Device Coatings
Mr. Charles W. Olson
Senior VP & President of Vascular Interventions
Ms. Teryl L. W. Sides
Corporate Controller, VP of Finance & Principal Accounting Officer
Mr. John D. Manders
Show More
Director of Corporate Development
Joel Suiter
Senior VP of Human Resources & President of In Vitro Diagnostics
Mr. Joseph J. Stich
Show Less

See Also

Discover More
What is the Intrinsic Value of one SRDX stock?

The intrinsic value of one SRDX stock under the Base Case scenario is 15.29 USD.

Is SRDX stock undervalued or overvalued?

Compared to the current market price of 39.33 USD, Surmodics Inc is Overvalued by 61%.

Back to Top